Due to a more favourable environment, MEDPACE HOLDINGS slightly increases to Neutral
MEDPACE HOLDINGS (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date February 11, 2022, the closing price was USD 174.90 and its target price was estimated at USD 151.96.Medpace Holdings is a holding company. Through its subsidiaries, the company is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company provides a range of services supporting the clinical development process from Phase I to Phase IV. The company provides these services across a range of therapeutic areas. The company's line of clinical development services includes, but is not limited to, study start-up, patient recruitment and retention, clinical monitoring, risk-based monitoring, medical writing, data management, pharmacovigilance, and molecular and genetic testing.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.